AI Analyst Summary
Sarepta Therapeutics is a loss-making biotech trading at a strikingly low forward P/E of 7.0x, suggesting the market is anticipating a meaningful earnings recovery — likely tied to commercialization milestones for its gene therapy pipeline, particularly Elevidys for Duchenne muscular dystrophy. However, a 34.3% YoY revenue decline and negative earnings make the bull case heavily contingent on future execution that has not yet materialized in the financials. The key risk is continued commercial underperformance, which could further erode analyst confidence and pressure the stock below current levels.
Fundamentals
Pe
No trailing P/E (loss-making); Forward P/E: 7.0x · 3.0/5
No trailing P/E due to current losses, but the forward P/E of 7.0x is strikingly low for a biotech, suggesting the market is pricing in a meaningful earnings recovery. Scored neutral given the loss-making status tempers what would otherwise be an attractive forward multiple.
Peg
PEG: -0.09 (negative — loss-making) · 2.0/5
A negative PEG of -0.09 reflects current negative earnings, rendering the ratio economically meaningless as a valuation signal. With revenue down 34.3% YoY and no positive earnings base, this dimension is a caution flag rather than a positive signal.
Analyst Rating
Hold (2.7) · 3.0/5
Consensus of 2.7 on the inverted scale maps to a Hold, sitting at the upper boundary of the Buy/Hold zone. With 23 analysts covering the stock — 8 Buy, 11 Hold, 5 Sell — sentiment is divided, reflecting genuine uncertainty around Sarepta's near-term trajectory. Capped at 3.
Earnings Trend
Revenue -34.3% YoY; Earnings growth N/A · 2.0/5
A 34.3% year-over-year revenue decline is a significant negative signal. Earnings growth is unavailable given the company is loss-making. While biotech revenues can be lumpy around product launches and milestones, this degree of top-line contraction warrants caution and scores below average.
Price Target Beat
EPS beat rate: 3 of 4 quarters · 2.0/5
With only 4 quarters of data available, the 3-of-4 beat rate is encouraging directionally but insufficient for a high-confidence score. Mapped conservatively to a score of 2 given the limited history and the context of ongoing losses.
Management
Mixed — moderate beat rate, declining revenue · 2.0/5
Management has beaten EPS estimates in 3 of the last 4 quarters, which shows some execution discipline, but the steep revenue decline and loss-making position raise questions about capital allocation and commercial strategy. Analyst sentiment is cautious, supporting a below-average management score.
● See the full picture
Get today's top-scored picks, ranked for you.
Compass screens thousands of stocks every morning and hands you a short list of high-conviction picks — scored, explained, and re-ranked to your risk profile.
Start free for 3 days →
No credit card. Then $9/month. Cancel anytime.
How Compass scores stocks
Compass pre-filters thousands of U.S. equities by fundamentals, then an AI analyst scores each finalist 1–5 across six measures — spanning valuation, growth, analyst sentiment, and management quality — into one composite score, refreshed every market morning. Browse all covered stocks →
Not financial advice.
Compass is an analytical tool, not a registered investment adviser or broker-dealer.
Scores and recommendations are generated by AI, may be inaccurate or out of date, and are
not investment, financial, legal, or tax advice. Investing involves risk, including loss of
principal. Do your own research and consult a licensed financial professional.
About Compass.